American Journal of Cardiology
Volume 99, Issue 10 , Pages 1399-1402 , 15 May 2007

Meta-Analysis of Randomized Trials of Drug-Eluting Stents Versus Bare Metal Stents in Patients With Diabetes Mellitus

  • Thomas F. Boyden, MD

      Affiliations

    • University Michigan Medical School, Ann Arbor VA Medical Center, Ann Arbor, Michigan
    • ,
  • Brahmajee K. Nallamothu, MD, MPH

      Affiliations

    • University Michigan Medical School, Ann Arbor VA Medical Center, Ann Arbor, Michigan
    • VA Health Services Research and Development Center of Excellence, Ann Arbor VA Medical Center, Ann Arbor, Michigan.
    • ,
  • Mauro Moscucci, MD

      Affiliations

    • University Michigan Medical School, Ann Arbor VA Medical Center, Ann Arbor, Michigan
    • ,
  • Paul S. Chan, MD, MSc

      Affiliations

    • University Michigan Medical School, Ann Arbor VA Medical Center, Ann Arbor, Michigan
    • ,
  • P. Michael Grossman, MD

      Affiliations

    • University Michigan Medical School, Ann Arbor VA Medical Center, Ann Arbor, Michigan
    • ,
  • Thomas T. Tsai, MD

      Affiliations

    • University Michigan Medical School, Ann Arbor VA Medical Center, Ann Arbor, Michigan
    • ,
  • Stanley J. Chetcuti, MD

      Affiliations

    • University Michigan Medical School, Ann Arbor VA Medical Center, Ann Arbor, Michigan
    • ,
  • Eric R. Bates, MD

      Affiliations

    • University Michigan Medical School, Ann Arbor VA Medical Center, Ann Arbor, Michigan
    • ,
  • Hitinder S. Gurm, MD

      Affiliations

    • University Michigan Medical School, Ann Arbor VA Medical Center, Ann Arbor, Michigan
    • Corresponding Author InformationCorresponding author: Tel.: 734-936-5544; fax: 734-764-4142.

Received 12 October 2006 ,Revised 28 December 2006 ,Accepted 28 December 2006.

References 

  1. Colombo A, Drzewiecki J, Banning A, Grube E, Hauptmann K, Silber S, et al. Randomized study to assess the effectiveness of slow- and moderate-release polymer-based paclitaxel-eluting stents for coronary artery lesions. Circulation. 2003;108:788–794
  2. Hermiller J, Raizner A, Cannon L, Gurbel P, Kutcher M, Wong S, et al. Outcomes with the polymer-based paclitaxel-eluting TAXUS stent in patients with diabetes mellitus: the TAXUS-IV trial. J Am Coll Cardiol. 2005;45:1172–1179
  3. Stone G, Ellis S, Cannon L, Mann J, Greenberg J, Spriggs D, et al. Comparison of a polymer-based paclitaxel-eluting stent with a bare metal stent in patients with complex coronary artery disease: a randomized controlled trial. JAMA. 2005;294:1215–1223
  4. Dawkins K, Grube E, Guagliumi G, Banning A, Zmudka K, Colombo A, et al Clinical efficacy of polymer-based paclitaxel-eluting stents in the treatment of complex, long coronary artery lesions from a multicenter, randomized trial: support for the use of drug-eluting stents in contemporary clinical practice. Circulation. 2005;112:3306–3313
  5. Sabate M, Jimenez-Quevedo P, Angiolillo D, Gómez-Hospital J, Alfonso F, Hernández-Antolín R, et al Randomized comparison of sirolimus-eluting stent versus standard stent for percutaneous coronary revascularization in diabetic patients: the diabetes and sirolimus-eluting stent (DIABETES) trial. Circulation. 2005;112:2175–2183
  6. Abizaid A, Costa M, Blanchard D, Albertal M, Eltchaninoff H, Guagliumi G, et al Sirolimus-eluting stents inhibit neointimal hyperplasia in diabetic patients (Insights from the RAVEL trial). Eur Heart J. 2004;25:107–112
  7. Ortolani P, Ardissino D, Cavallini C, Bramucci E, Indolfi C, Aquilina M, et al. Effect of sirolimus-eluting stent in diabetic patients with small coronary arteries (a SES-SMART substudy). Am J Cardiol. 2005;96:1393–1398
  8. Holmes D, Leon M, Moses J, Popma J, Cutlip D, Fitzgerald P, et al. Analysis of 1-year clinical outcomes in the SIRIUS trial: a randomized trial of a sirolimus-eluting stent versus a standard stent in patients at high risk for coronary restenosis. Circulation. 2004;109:634–640
  9. Schampaert E, Cohen E, Schluter M, Reeves F, Traboulsi M, Title L, et al. The Canadian study of the sirolimus-eluting stent in the treatment of patients with long de novo lesions in small native coronary arteries (C-SIRIUS). J Am Coll Cardiol. 2004;43:1110–1115
  10. Schofer J, Schluter M, Gershlick A, Wijns W, Garcia E, Schampaert E, et al. Sirolimus-eluting stents for treatment of patients with long atherosclerotic lesions in small coronary arteries: double-blind, randomised controlled trial (E-SIRIUS). Lancet. 2003;362:1093–1099
  11. Urban P, Gershlick A, Guagliumi G, Guyon P, Lotan C, Schofer J, et al. Safety of coronary sirolimus-eluting stents in daily clinical practice: one-year follow-up of the e-Cypher registry. Circulation. 2006;113:1434–1441
  12. Kelbaek H, Thuesen L, Helqvist S, Kløvgaard L, Jørgensen E, Aljabbari S, et al. The stenting coronary arteries in non-stress/benestent disease (SCANDSTENT) trial. J Am Coll Cardiol. 2006;47:449–455
  13. Schampaert E. Sirolimus-eluting stents in diabetics: SIRIUS, C-SIRIUS and E-SIRIUS. Available at: http://www.tctmd.com/csportal/appmanager/tctmd/main?_nfpb=true&_pageLabel=TCTMDContent&hdCon=809006. Accessed July 4, 2006.
  14. Hermiller J. Diabetic results: Taxus II, IV & VI. Available at: http://www.tctmd.com/csportal/appmanager/tctmd/main?_nfpb=true&_pageLabel=TCTMDContent&hdCon=808567. Accessed July 4, 2006.
  15. Popma J. Update on the Taxus trials: continued safety and efficacy. Available at: http://www.tctmd.com/csportal/appmanager/tctmd/main?_nfpb=true&_pageLabel=TCTMDContent&hdCon=1352036. Accessed July 4, 2006.
  16. Moussa I, Leon MB, Baim DS, O’Neill W, Popma J, Buchbinder M, et al. Impact of sirolimus-eluting stents on outcome in diabetic patients: a SIRIUS (SIRolImUS-coated bx velocity balloon-expandable stent in the treatment of patients with de novo coronary artery lesions) substudy. Circulation. 2004;109:2273–2278
  17. Gurm HS, Lincoff AM, Lee D, Tang W, Jia G, Booth J, et al Outcome of acute ST-segment elevation myocardial infarction in diabetics treated with fibrinolytic or combination reduced fibrinolytic therapy and platelet glycoprotein IIb/IIIa inhibition: lessons from the GUSTO V trial. J Am Coll Cardiol. 2004;43:542–548
  18. Malmberg K, Yusuf S, Gerstein H, Brown J, Zhao F, Hunt D, et al. Impact of diabetes on long-term prognosis in patients with unstable angina and non-Q-wave myocardial infarction: results of the OASIS (Organization to Assess Strategies for Ischemic Syndromes) Registry. Circulation. 2000;102:1014–1019
  19. Morris J, Smith L, Jones R, Glower D, Morris P, Muhlbaier L, et al. Influence of diabetes and mammary artery grafting on survival after coronary bypass. Circulation. 1991;84:275–284
  20. Gurm H, Sarembock I, Kereiakes D, Young J, Harrington R, Kleiman N, et al. Use of bivalirudin during percutaneous coronary intervention in patients with diabetes mellitus: an analysis from the randomized evaluation in percutaneous coronary intervention linking angiomax to reduced clinical events (REPLACE)-2 trial. J Am Coll Cardiol. 2005;45;:1932–1938
  21. Flaherty J, Davidson C. Diabetes and coronary revascularization. JAMA. 2005;293:1501–1508
  22. Kornowski R, Mintz G, Kent K, Pichard A, Satler L, Bucher T, et al. Increased restenosis in diabetes mellitus after coronary interventions is due to exaggerated intimal hyperplasia (A serial intravascular ultrasound study). Circulation. 1997;95:1366–1369
  23. Ledru F, Ducimetiere P, Battaglia S, Courbon D, Beverelli F, Guize L, et al. New diagnostic criteria for diabetes and coronary artery disease: insights from an angiographic study. J Am Coll Cardiol. 2001;37:1543–1550
  24. Moreno P, Fuster V. New aspects in the pathogenesis of diabetic atherothrombosis. J Am Coll Cardiol. 2004;44:2293–2300
  25. Writing Group for the Bypass Angioplasty Revascularization Investigation (BARI) Investigators. Five-year clinical and functional outcome comparing bypass surgery and angioplasty in patients with multivessel coronary disease (A multicenter randomized trial). JAMA. 1997;277:715–721
  26. Rozenman Y, Sapoznikov D, Mosseri M, Gilon D, Lotan C, Nassar H, et al. Long-term angiographic follow-up of coronary balloon angioplasty in patients with diabetes mellitus: a clue to the explanation of the results of the BARI study (Balloon Angioplasty Revascularization Investigation). J Am Coll Cardiol. 1997;30:1420–1425
  27. Van Belle E, Ketelers R, Bauters C, Perie M, Abolmaali K, Richard F, et al. Patency of percutaneous transluminal coronary angioplasty sites at 6-month angiographic follow-up: a key determinant of survival in diabetics after coronary balloon angioplasty. Circulation. 2001;103:1218–1224
  28. Dibra A, Kastrati A, Mehilli J, Pache J, Schuhlen H, von Beckerath N, et al. Paclitaxel-eluting or sirolimus-eluting stents to prevent restenosis in diabetic patients. N Engl J Med. 2005;353:663–670
  29. Stettler C, Allemann S, Egger M, Windecker S, Meier B, Diem P. Efficacy of drug eluting stents in patients with and without diabetes mellitus: indirect comparison of controlled trials. Heart. 2006;92:650–657
  30. Tung R, Kaul S, Diamond G, Shah P. Narrative review: drug-eluting stents for the management of restenosis: a critical appraisal of the evidence. Ann Intern Med. 2006;144:913–919

PII: S0002-9149(07)00261-5

doi: 10.1016/j.amjcard.2006.12.069

American Journal of Cardiology
Volume 99, Issue 10 , Pages 1399-1402 , 15 May 2007

Article Tools

* Image Usage & Resolution